Medical disclaimer

Chemo-Immunotherapy Before Surgery for Triple-Negative Breast Cancer: Ichilov Study

In this retrospective study of 127 patients, those with a germline BRCA mutation who received chemo-immunotherapy (KN522) had a pathologic complete response (pCR, no cancer found in the removed tissue) rate of 92.3%, but the group also had more hospitalizations and neutropenic fever. The patients were treated at the Oncology Institute of Tel Aviv Medical Center, which is the same hospital listed on Bookimed as Sourasky Medical Center (Ichilov) in Tel Aviv.

9 min read

Prepared by Bookimed editorial team

Medical content and care coordination

Sourasky Medical Center (Ichilov)
← All research summaries
Published research, not an individual patient story.

The source identifies treatment at the named clinic. Study results describe this cohort, not a predicted individual outcome.

Key takeaways

  • The study compared KN522 (pembrolizumab plus doxorubicin, cyclophosphamide, carboplatin and paclitaxel) with the same chemotherapy without pembrolizumab (ACTC) in stage II-III triple-negative breast cancer.
  • pCR was 92.3% in BRCA-mutation carriers on KN522, versus 60.4%, 55.6% and 36.7% in the other three groups.
  • Both the KN522 protocol and BRCA mutation status were independent predictors of pCR in the authors' analysis.
  • KN522 was associated with more hospitalizations (40.5% vs. 14.6%) and more neutropenic fever (32.9% vs. 2.1%).
  • These are group results from one center and are not a forecast for any individual patient.

The question this study addresses

This retrospective analysis looked at 127 patients with stage II-III triple-negative breast cancer treated at a single tertiary medical center, the Oncology Institute of Tel Aviv Medical Center. Patients received either KN522 or ACTC before surgery. The authors split them into four groups by treatment and by germline BRCA mutation status. They compared pCR rates, survival and toxicity. Bookimed did not run the study.

The situation
Adults with stage II-III triple-negative breast cancer who were treated before surgery, with or without a germline BRCA mutation.
The treatment
Chemo-immunotherapy KN522 (pembrolizumab plus doxorubicin, cyclophosphamide, carboplatin and paclitaxel) compared with the same chemotherapy without pembrolizumab (ACTC).

What this evidence cannot establish

  • The study is retrospective and comes from a single center, so groups may differ in ways the analysis cannot fully remove.
  • The abstract does not state the follow-up duration, and survival and toxicity are not reported for each subgroup alone.
  • The treating site is Tel Aviv Medical Center, which appears to be the same hospital as the Bookimed clinic profile under another name; this page does not show how any individual patient would do at the clinic.

Patient groups in the published study

26 patients · Published study group

BRCA-mutation carriers given KN522 before surgery

Indication
Stage II-III triple-negative breast cancer with a germline BRCA mutation
Treatment
KN522: pembrolizumab plus doxorubicin, cyclophosphamide, carboplatin and paclitaxel

26 patients

Patients with a germline BRCA mutation who were treated with chemo-immunotherapy before surgery.

KN522 before surgery.

  • Pathologic complete response (pCR) rate

    92.3%

    26 patients · Study group

    not stated

Reported risks

  • Study-wide, KN522 was associated with more hospitalizations and more neutropenic fever than ACTC; the abstract does not give these figures for this subgroup alone.

Limits of this evidence

  • The pCR rate was 92.3% in this small group of 26 patients; survival and toxicity for this subgroup alone are not reported.

For a clinic assessment

  • Pathology report and stage of the cancer
  • Germline BRCA test result

53 patients · Published study group

BRCA wildtype patients given KN522 before surgery

Indication
Stage II-III triple-negative breast cancer, BRCA wildtype
Treatment
KN522: pembrolizumab plus doxorubicin, cyclophosphamide, carboplatin and paclitaxel

53 patients

Patients without a BRCA mutation who were treated with chemo-immunotherapy before surgery.

KN522 before surgery.

  • Pathologic complete response (pCR) rate

    60.4%

    53 patients · Study group

    not stated

Reported risks

  • Study-wide, KN522 was associated with more hospitalizations and more neutropenic fever than ACTC; the abstract does not give these figures for this subgroup alone.

Limits of this evidence

  • The pCR rate was 60.4% in this group; survival and toxicity for this subgroup alone are not reported.

For a clinic assessment

  • Pathology report and stage of the cancer
  • Germline BRCA test result showing no mutation

18 patients · Published study group

BRCA-mutation carriers given ACTC before surgery

Indication
Stage II-III triple-negative breast cancer with a germline BRCA mutation
Treatment
ACTC: doxorubicin, cyclophosphamide, carboplatin and paclitaxel, without pembrolizumab

18 patients

Patients with a germline BRCA mutation who were treated with chemotherapy alone before surgery.

ACTC before surgery, without pembrolizumab.

  • Pathologic complete response (pCR) rate

    55.6%

    18 patients · Study group

    not stated

Reported risks

  • Study-wide, ACTC was associated with fewer hospitalizations and less neutropenic fever than KN522; the abstract does not give figures for this subgroup alone.

Limits of this evidence

  • The pCR rate was 55.6% in this small group of 18 patients; survival and toxicity for this subgroup alone are not reported.

For a clinic assessment

  • Pathology report and stage of the cancer
  • Germline BRCA test result

30 patients · Published study group

BRCA wildtype patients given ACTC before surgery

Indication
Stage II-III triple-negative breast cancer, BRCA wildtype
Treatment
ACTC: doxorubicin, cyclophosphamide, carboplatin and paclitaxel, without pembrolizumab

30 patients

Patients without a BRCA mutation who were treated with chemotherapy alone before surgery.

ACTC before surgery, without pembrolizumab.

  • Pathologic complete response (pCR) rate

    36.7%

    30 patients · Study group

    not stated

Reported risks

  • Study-wide, ACTC was associated with fewer hospitalizations and less neutropenic fever than KN522; the abstract does not give figures for this subgroup alone.

Limits of this evidence

  • The pCR rate was 36.7% in this group; survival and toxicity for this subgroup alone are not reported.

For a clinic assessment

  • Pathology report and stage of the cancer
  • Germline BRCA test result showing no mutation

Results and limits of the study

The pCR rate was 92.3% with KN522 in BRCA-mutation carriers, compared with 60.4% (KN522, BRCA wildtype), 55.6% (ACTC, BRCA mutation) and 36.7% (ACTC, BRCA wildtype). In the multivariable analysis, the KN522 protocol (OR 3.69) and BRCA mutation status (OR 3.78) were independent predictors of pCR. Reaching pCR was linked to better event-free and overall survival in univariate analyses, but in multivariable models it remained a significant independent predictor of overall survival only. The authors conclude that supportive care, including G-CSF (a drug that helps white blood cell counts recover), should be considered.

Risks reported by the source

  • KN522 was associated with higher hospitalization rates (40.5% vs. 14.6%) and more neutropenic fever, meaning fever with low white blood cell counts (32.9% vs. 2.1%).
  • The authors link this likely to lower G-CSF use during the doxorubicin and cyclophosphamide part of KN522 (21.5% vs. 68.8%).

Limitations and unknowns

  • How long patients were followed is not stated in the abstract.
  • Survival and toxicity for each of the four groups alone are not reported.
  • The abstract does not say how the results apply to patients treated elsewhere or to any one person.
  • Whether better G-CSF use would reduce hospitalizations was not tested in this analysis.

What to clarify in your treatment plan

Before booking, ask the clinic which treatment protocol would be considered for your case and who would make that decision. Ask how supportive care, such as G-CSF, is planned and how fever or infection signs are handled between visits. Also ask which documents the team needs, such as pathology and BRCA test reports.

Sourasky Medical Center (Ichilov): clinic profile

Sourasky Medical Center (Ichilov)

Sourasky Medical Center (Ichilov)

Tel Aviv, Israel

4.5/5 · 172 Bookimed reviews (current clinic profile)

Sonnenblick Amir: doctor profile

  • Amir Sonnenblick is listed as the eighth author of the study, and his affiliation is the Oncology Institute, Tel Aviv Medical Center, and Tel Aviv University.
Sonnenblick Amir

Sonnenblick Amir

Clinical oncologist

19 years of experience

Safety and recovery: general information

General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.

Possible side effects

  • Chemotherapy may cause hair loss, nail changes, mouth sores, appetite or weight changes, nausea, vomiting, diarrhea, extreme tiredness and numbness or tingling in hands or feet.

    Ask the care team how these effects are usually managed.

  • Some chemo drugs, such as doxorubicin, can cause permanent heart damage.

    Ask whether heart checks are planned.

  • Chemotherapy may affect menstrual periods, in some cases permanently, and some people may lose the ability to get pregnant.

    Discuss fertility plans with the care team before treatment starts.

  • In very rare cases, doxorubicin and certain other chemo drugs can cause bone marrow diseases such as myelodysplastic syndromes or acute myeloid leukemia.

    Ask about long-term monitoring.

Recovery and aftercare

  • Chemotherapy given before or after surgery is often given for a total of 3 to 6 months, depending on the drugs used.

    Ask for the expected schedule for your protocol.

  • Side effects usually go away after treatment ends, and there are often ways to reduce them.

    Ask what support is offered during treatment.

Suitability and cautions

  • Chemotherapy is not an option for everyone, and a doctor's recommendation depends on the cancer's characteristics, health history and personal preferences.

    Your oncologist decides what fits your case.

  • Some treatment can lead to more problems with low blood cell counts, so it may not be an option for everyone.

    Ask how your blood counts would be monitored.

When to contact the clinic

  • Call your care team now if you have a high temperature, feel hot, cold, sweaty or shivery, or have other signs of infection such as a sore throat or cough.

    Do not wait for the next scheduled visit.

  • Call your care team now if you have a painful, swollen, warm leg or arm, or sudden breathlessness, sharp chest pain or coughing up blood.

    Contact your care team without delay.

Request a personal plan from the clinic

Ask Sourasky Medical Center (Ichilov) about chemotherapy planning for triple-negative breast cancer and a document review

Bookimed shares your pathology and BRCA reports with the clinic and asks which protocol and supportive care the oncology team would consider. The clinic gives the medical opinion.

Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.

Frequently asked questions

Who ran this study and where were the patients treated?

The study was run by authors from the Oncology Institute of Tel Aviv Medical Center in Tel Aviv, Israel. The abstract describes a single tertiary medical center. Tel Aviv Medical Center appears to be the same hospital as Sourasky Medical Center (Ichilov), which is the clinic profile on Bookimed. Amir Sonnenblick, a doctor matched to this clinic, is one of the authors. Bookimed did not run or fund the study; this page summarizes the published abstract only.

What did the study find about BRCA-mutation carriers on KN522?

Among 26 BRCA-mutation carriers who received KN522, the pCR rate was 92.3%. The other groups had 60.4%, 55.6% and 36.7%. In the multivariable analysis, both KN522 and BRCA mutation status were independent predictors of pCR. These are group results from one center in a retrospective analysis. They do not predict what would happen for an individual patient, and the abstract does not state follow-up duration.

What side effects did KN522 show compared with ACTC?

KN522 was associated with more hospitalizations (40.5% vs. 14.6%) and more neutropenic fever (32.9% vs. 2.1%). Neutropenic fever means a fever with low white blood cell counts. The authors say this was likely due to lower G-CSF prophylaxis during the doxorubicin and cyclophosphamide part of KN522 (21.5% vs. 68.8%). They call for supportive care optimization, including G-CSF consideration. Ask your care team how infection risk is handled.

Does this study show that KN522 will work for me?

No. The study reports group results from a retrospective analysis at one center, and it cannot promise an outcome for any individual. Whether chemotherapy is recommended depends on the cancer's characteristics, your health history and your preferences. Pathologic complete response was linked to survival in the authors' analyses, but the abstract does not state follow-up duration. Your oncologist should review your own reports and decide on a plan.

Sources and scope

This page was prepared from the published abstract of the study, its extracted subgroup results and general patient information from named medical sources. Bookimed did not run the study and added no new data.

  1. 1. Etan et al. – Efficacy and toxicity of neoadjuvant chemotherapy versus chemo-immunotherapy in triple-negative breast cancer patients with and without germline BRCA mutations.

    Retrospective single-center cohort comparison · 2026

    127 adults with stage II-III triple-negative breast cancer, with or without germline BRCA mutation

    Follow-up: Not stated in the abstract

    Only the abstract was used, so details on follow-up, subgroup survival and subgroup toxicity are not available.

  2. 2. American Cancer Society
  3. 3. NHS
  4. 4. Breast Cancer Organization (breastcancer.org)
  5. 5. Sourasky Medical Center (Ichilov) on Bookimed
  6. 6. Sonnenblick Amir on Bookimed

Scope and limitations

  • A research summary is not an individual medical recommendation.
  • Group results describe the study participants, not a forecast for any one patient.

Related procedures

About the editorial team

Bookimed editorial team

Prepared by

Bookimed editorial team

Medical content and care coordination

Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.

About this page

This page summarizes cited evidence and links to current Bookimed provider profiles. It does not replace an individual diagnosis or treatment plan. Published group results are not a guarantee of your outcome.

Clinic profiles and package availability come from the current Site catalog. Historical costs and research measurements keep their original context.

Report a correction